KOS PHARMACEUTICALS
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The companyโs principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos๏ฟฝ... ๏ฟฝ๏ฟฝ strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The company currently markets Niaspan, Advicor, Azmacort, Cardizem LA, Teveten and Teveten HCT. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.
KOS PHARMACEUTICALS
Social Links:
Industry:
Health Care Medical Pharmaceutical
Founded:
1988-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Total Employee:
1001+
Status:
Active
Total Funding:
0
Similar Organizations
Acuity Pharmaceuticals
Acuity Pharmaceuticals product-focused ophthalmic pharmaceutical company applying its proprietary technology to the treatment.
Eleison Pharmaceuticals
Eleison Pharmaceuticals acquires, develops, and commercializes clinical stage drug candidates for "orphan" cancers.
Investors List
Bill Pruitt
Bill Pruitt investment in Seed Round - KOS Pharmaceuticals
More informations about "KOS Pharmaceuticals"
Abbott to acquire Kos Pharmaceuticals for $3.7 billion - Reliable โฆ
Abbott and Kos Pharmaceuticals Inc. on November 6 announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net โฆSee details»
Office of Public Affairs | Kos Pharmaceuticals to Pay More Than โฆ
Dec 7, 2010 From 2002 to 2004, Kos made a series of payments to the two doctors or a third party intermediary in the form of โsponsorshipโ of continuing medical education classes โฆSee details»
Kos Pharmaceuticals, Inc - Encyclopedia.com
KOS Pharmaceuticals, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KOS Pharmaceuticals, Inc. of Cranbury, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Kos Pharmaceuticals Profile: Summary โข OpenSecrets
Kos Pharmaceuticals organization profile. Contributions in the 2022 cycle: $100. Lobbying in 2022: $0. Outside Spending in the 2022 cycle: $0.See details»
Kos Pharmaceuticals Company Profile 2024: Valuation, Investors ...
Kos Pharmaceuticals General Information Description. Manufacturer of prescription products for the treatment of chronic cardiovascular diseases. The company's products are used treatment โฆSee details»
Kos Pharmaceuticals Company Profile | Management and
Kos Pharmaceuticals Profile and History Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and โฆSee details»
KOS Pharmaceuticals Inc - Company Profile and News
Company profile page for KOS Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
KOS Pharmaceuticals - Funding, Financials, Valuation & Investors
Jan 1, 2004 KOS Pharmaceuticals is a pharmaceutical company that manufactures prescription products. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. โฆSee details»
KOS PHARMACEUTICALS, INC. - SEC.gov
KOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) FLORIDA : 65-0670898 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. โฆSee details»
Abbott Laboratories To Expand Presence In Lipid Management
Nov 6, 2006 "Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially," said Miles D. White, chairman and chief executive officer, Abbott. ... "This is an โฆSee details»
Abbott To Buy Kos Pharmaceuticals for $3.7 Billion - PharmTech
Nov 9, 2006 Abbott Park, IL (Nov. 6)-Abbott Laboratories (www.abbott.com) agreed to acquire the specialty pharmaceutical company Kos Pharmaceuticals, Inc. (Cranbury, NJ, โฆSee details»
Abbott Labs Buying Kos Pharmaceuticals in $3.7 Billion Deal
Nov 7, 2006 CHICAGO, Nov. 6 โ Abbott Laboratories said on Monday that it would acquire Kos Pharmaceuticals for $3.7 billion. Abbott plans to buy Kos, based in Cranbury, N.J., for $78 a โฆSee details»
KOS PHARMACEUTICALS Careers and Employment - Indeed
Find out what works well at KOS PHARMACEUTICALS from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. ... My managers were โฆSee details»
KOS PHARMACEUTICALS, INC. FORM 10-K - SEC.gov
The aggregate market value of Kos Pharmaceuticals, Inc. Common Stock, $.01 par value, held by non-affiliates, computed by reference to the price at which the stock was sold as of February โฆSee details»
Kos Pharmaceuticals gets $50 million boost
Dec 20, 1999 Kos said it will also be able to aggressively promote its current range of products: Niaspan (niacin), which was recently approved in the USA for the elevation of protective high โฆSee details»
Breath Coordinated Inhaler - Nectar Product Development
KOS Pharmaceuticals, a leader in the development of inhalation medication delivery technologies and now part of Abbott Labs, needed to develop a breath-coordinated inhaler that would โฆSee details»
From Side Hustle To A Driving Force In The Plant-Based โฆ
Apr 26, 2021 Over time, KOS has grown from its initial two SKUs as a side hustle to the duoโs electronic business, to 20 SKUs in 2019, expanding beyond e-commerce to retailers โฆSee details»
KOS Secures $12 Million Investment to Proliferate the Brand's โฆ
SANTA BARBARA, Calif., Feb. 15, 2022 /PRNewswire/ -- KOS, the plant-based powerhouse and functional nutrition brand, announces today the closing of its milestone $12 million Series A โฆSee details»